The estimated Net Worth of Jacob Steven Leach is at least $68.6 Миллион dollars as of 9 September 2024. Mr Leach owns over 746 units of Dexcom Inc stock worth over $18,138,730 and over the last 8 years he sold DXCM stock worth over $49,430,282. In addition, he makes $1,004,087 as Exec. VP & CTO at Dexcom Inc.
Mr has made over 25 trades of the Dexcom Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 746 units of DXCM stock worth $51,586 on 9 September 2024.
The largest trade he's ever made was buying 150,000 units of Dexcom Inc stock on 16 August 2021 worth over $229,500. On average, Mr trades about 10,165 units every 62 days since 2017. As of 9 September 2024 he still owns at least 264,915 units of Dexcom Inc stock.
You can see the complete history of Mr Leach stock trades at the bottom of the page.
Jacob Steven Leach is the Exec. VP & CTO at Dexcom Inc.
As the Exec. VP & CTO of Dexcom Inc, the total compensation of Mr Leach at Dexcom Inc is $1,004,087. There are 7 executives at Dexcom Inc getting paid more, with Kevin Sayer having the highest compensation of $10,279,400.
Mr Leach is 43, he's been the Exec. VP & CTO of Dexcom Inc since . There are 23 older and 6 younger executives at Dexcom Inc. The oldest executive at Dexcom Inc is Andrew K. Balo, 73, who is the Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel..
Jacob's mailing address filed with the SEC is 6340, Sequence Drive, Sorrento Valley, San Diego, San Diego County, California, 92121, United States.
Over the last 20 years, insiders at Dexcom Inc have traded over $724,717,982 worth of Dexcom Inc stock and bought 165,450 units worth $3,489,100 . The most active insiders traders include Sean Carney, Kim D Blickenstaff и Steven R Altman. On average, Dexcom Inc executives and independent directors trade stock every 7 days with the average trade being worth of $892,438. The most recent stock trade was executed by Sadie Stern on 9 September 2024, trading 426 units of DXCM stock currently worth $29,458.
founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.
Dexcom Inc executives and other stock owners filed with the SEC include: